Schenkein David P 4

What Happened

• David P. Schenkein, a director of Prime Medicine, was granted a derivative award (listed as an acquisition) for 75,000 shares on 2026-06-05. The filing shows an acquisition price of $0.00, indicating an option-style award rather than an open-market purchase or sale.
• Total cash value reported at grant: $0 (award/option). This is a grant of equity compensation, not a sale—such awards are routine for directors and employees and do not by themselves indicate a buy or sell sentiment.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-08 (filed timely).
• Transaction code: A (award/grant of a derivative security).
• Price reported: $0.00 per share; 75,000 shares granted.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The shares subject to this option vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person’s continuous service through such vesting date.

Context

• This was an equity award (option) to a director with a time-based vesting condition. It was not an immediate sale or cash exercise; therefore it doesn’t represent an immediate change in market holdings.
• For retail investors, awards to directors are common compensation and should be viewed as routine unless paired with significant insider purchases or sales or unusual vesting/exercise terms.